Xuebing Di
Overview
Explore the profile of Xuebing Di including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu Q, Feng L, Wang Y, Mao Y, Di X, Zhang K, et al.
Signal Transduct Target Ther
. 2022 Aug;
7(1):270.
PMID: 35989380
Alternative RNA splicing is one of the most important mechanisms of posttranscriptional gene regulation, which contributes to protein diversity in eukaryotes. It is well known that RNA splicing dysregulation is...
2.
Zhang Y, Guo L, Dai Q, Shang B, Xiao T, Di X, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35688556
Background: Neutrophil extracellular traps (NETs) were originally thought to be formed by neutrophils to trap invading microorganisms as a defense mechanism. Increasing studies have shown that NETs play a pivotal...
3.
Zhang Y, Zhu Y, Wang J, Xu Y, Wang Z, Liu Y, et al.
Cancer Immunol Immunother
. 2021 Aug;
71(3):675-688.
PMID: 34342668
Many nasopharyngeal carcinoma (NPC) patients develop distant metastases after treatment, leading to poor outcomes. To date, there are no peripheral biomarkers suitable for all NPC patients to predict distant metastasis....
4.
Zhang Y, Di X, Chen G, Liu J, Zhang B, Feng L, et al.
Am J Cancer Res
. 2021 May;
11(4):1267-1285.
PMID: 33948357
Although the classic molecular subtype of breast cancer (BRCA) has been widely used in clinical diagnosis, as a highly heterogeneous malignant tumor, the classic scheme is not enough to accurately...
5.
Wang J, Bie Z, Zhang Y, Li L, Zhu Y, Zhang Y, et al.
Oncoimmunology
. 2021 Apr;
10(1):1899609.
PMID: 33796410
An indicator for systemic evaluation of the adaptive immune status is lacking. Peripheral blood is important in antitumour immunity, and the T-cell receptor (TCR) repertoire diversity is key for effective...
6.
Zhang Y, Wu X, Zhang C, Wang J, Fei G, Di X, et al.
J Pathol
. 2020 Mar;
251(2):135-146.
PMID: 32207854
Intestinal-type gastric cancer (IGC) has a clear and multistep histological evolution. No studies have comprehensively explored gastric tumorigenesis from inflammation through low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia (HGIN)...
7.
Zhang Y, Liu F, Zhang C, Ren M, Kuang M, Xiao T, et al.
Am J Pathol
. 2019 Oct;
190(1):37-47.
PMID: 31610177
Triple-negative breast cancer (TNBC) is a heterogeneous disease with an unfavorable prognosis and no specific targeted therapies. The role of non-SMC condensin I complex subunit D2 (NCAPD2), a regulatory subunit...
8.
Wen L, Guo L, Zhang W, Li Y, Jiang W, Di X, et al.
Front Oncol
. 2019 Jul;
9:504.
PMID: 31263677
Most renal cell carcinoma (RCC) patients die from metastasis or recurrence after the spread of cancer to another organ, but the mechanisms underlying the intravascular survival of circulating tumor cells...
9.
Guo L, Chen G, Zhang W, Zhou L, Xiao T, Di X, et al.
Breast Cancer Res Treat
. 2019 Feb;
175(2):459-472.
PMID: 30778902
Purpose: Breast cancer is a heterogeneous disease, and although advances in molecular subtyping have been achieved in recent years, most subtyping strategies target individual genes independent of one another and...
10.
Wang Y, Guo L, Feng L, Zhang W, Xiao T, Di X, et al.
Oncol Rep
. 2018 Mar;
39(5):2147-2159.
PMID: 29565466
Circulating tumour cell (CTC) behaviours are distinct from those of bulk tissues. Thus, treatments to eliminate CTCs differ from the regimens followed to reduce the primary tumour and its metastases....